Funding for this research was provided by:
National Institute on Drug Abuse (UG1 DA015815)
Received: 3 May 2021
Accepted: 1 November 2021
First Online: 10 November 2021
: The Advarra Institutional Review Board reviewed the study protocol, qualitative interview guides, and information sheet.
: Not applicable.
: Alkermes (a global biopharmaceutical company) donated the extended-release naltrexone used in the study protocol. The authors report no additional competing interests.